On Friday shares of Regions Financial Corporation (NYSE:RF) closed at $9.58. Company’s sales growth for last 5 years was -7.40% and EPS growth for next 5 years is recorded as 8.54%. RBC Capital cut shares of Regions Financial Corp (NYSE:RF) from an outperform rating to a sector perform rating in a research report sent to investors on Wednesday morning, TheFlyOnTheWall.com reports.
Celgene Corporation (NASDAQ:CELG) in last trading activity advanced 2.26% to close at $118.71. Company weekly performance is 4.62% while its quarterly performance stands at -4.18%. Celgene Corporation (NASDAQ:CELG) is -8.02% away from its 52 week high. Celgene International II Sàrl, a wholly-owned subsidiary of Celgene Corp. (NASDAQ:CELG), Friday said it has entered into a strategic collaboration with MedImmune Limited, a wholly-owned subsidiary of AstraZeneca Plc. (AZN, AZN.L), to develop and commercialize an anti-PD-L1 inhibitor, MEDI4736, for hematologic malignancies.
On last trading day TAL Education Group (NYSE:XRS) decreased -1.74% to close at $36.24. Its volatility for the week is 1.84% while volatility for the month is 2.06%. XRS’s sales growth for past 5 years was 53.20% and its EPS growth for past 5 years was 72.30%. TAL Education Group (NYSE:XRS) monthly performance is 8.31%. TAL Education Group (NYSE:XRS) announced that it will release its unaudited financial results for the fourth quarter and fiscal year 2015 ended February 28, 2015, before the market opens on Tuesday, April 28, 2015.
AbbVie Inc. (NYSE:ABBV) has 0.10% insider ownership while its institutional ownership stands at 73.10%. In last trading activity company’s stock closed at $66.07. AbbVie (NYSE:ABBV) has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) and granted priority review for the company’s, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV). The NDA is for the treatment of adults with chronic genotype 4 (GT4) hepatitis C virus (HCV) infection.
On last trading day Inogen, Inc. (NASDAQ:INGN) advanced 0.30% to close at $37.13. Its volatility for the week is 2.53% while volatility for the month is 4.09%. Inogen, Inc. (NASDAQ:INGN) monthly performance is 15.78%. Inogen, Inc. (NASDAQ:INGN), announced that it will release its financial results for the fourth quarter and full year of 2014 before market open on Monday, April 27, 2015.